Catalog Advanced Search

Search by Categories
Search by Format
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • 2019 ACCP Journal of Clinical Pharmacology Journal CE | Monthly CE Offerings

    Contains 48 Component(s), Includes Credits

    The American College of Clinical Pharmacology® monthly journal article continuing education offerings from The Journal of Clinical Pharmacology.

    Registration and Pricing

    The American College of Clinical Pharmacology® (ACCP) offers a monthly article from the The Journal of Clinical Pharmacology (JCP) for continuing education credit. See the CE Info tab for more information on credits. The ACCP JCP Journal CE articles are priced and packaged for January through December of the same calendar year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once registered, learners have access to all of the Journal CE articles for the calendar year as the articles are released.

    To register, log into your ACCP online profile and then register by clicking the green Register button at the top right. Follow the online prompts to complete the registration process and to receive your registration confirmation. If you do not have an ACCP profile, one must be created before you can register for the Journal CE articles. If you do not know if you have a profile, please contact KLevy@ACCP1.org for further information to avoid creating duplicate profiles. Please address all other questions to CE@ACCP1.org.

    Requirements for Credits

    All requirements for claiming CE credits are listed in the CE Info tab. Continuing education credits and certificates must be claimed within 30-days of completing the monthly article offering. Continuing Pharmacy Education (CPE) data is uploaded into the CPE Monitor at the end of each month. The pharmacist's NABP# and MMDD of birth must be updated into their ACCP Profile or emailed to CE@ACCP1.org in order to have CPE credits automatically uploaded to the CPE Monitor.

    CE Expiration 12/31/2021




     

  • 2019 ACCP Virtual Journal Club November |Adverse Drug Reactions in Pediatrics: From Identification to Solutions using a National Active Surveillance Network - ON DEMAND

    Contains 5 Component(s), Includes Credits

    Presented by: Bruce Carleton, BSc, PharmD, FCP, FISPE, Professor and Chair, University of British Columbia & Reno Tanoshima, MD, PhD, Research Associate Dept of Pediatrics, Univ of British Columbia, BC Children's Hospital Research Institute

    Adverse Drug Reactions in Pediatrics: From Identification to Solutions using a National Active Surveillance Network - ON DEMAND

    ACCP Virtual Journal Club Webinars

    On Demand: November 6, 2019 to November 7, 2022

    See Handouts tab for Continuing Education information on IPCE credits.


  • 2019 ACCP Virtual Journal Club August | β2‐Adrenergic Receptor Gene Affects the Heart Rate Response of β‐Blockers: Evidence From 3 Clinical Studies - ON DEMAND

    Contains 5 Component(s), Includes Credits

    Presented by: Mohamed Shahin, BPharm, MS, PhD, MBI, Manager, Clinical Pharmacology Lead, Global Product Development, Pfizer Inc

    β-Adrenergic Receptor Gene Affects the Heart Rate Response of β-Blockers: Evidence From 3 Clinical Studies - ON DEMAND

    ACCP Virtual Journal Club Webinars

    Live Session: Wednesday, August 28, 2019 from 2:00-3:00 PM ET

    On Demand: August 30, 2019 to August 30, 2022

    See Handouts tab for Continuing Education information on CME and CPE credits.


  • 2019 ACCP Virtual Journal Club June | Toward Better Understanding of Insulin Therapy by Translation of a PK-PD Model to Visualize Insulin and Glucose Action Profiles - ON DEMAND

    Contains 5 Component(s), Includes Credits

    Presented by: Karen Schneck, PharmD, Research Scientist, Eli Lilly & Co, Pharmacometrics

    Toward Better Understanding of Insulin Therapy by Translation of a PK-PD Model to Visualize Insulin and Glucose Action Profiles - ON DEMAND

    ACCP Virtual Journal Club Webinars

    Live Session: Wednesday, June 26, 2019 from 2:00-3:00 PM EDT

    On Demand: June 27, 2019 to June 26, 2022

    See Handouts tab for Continuing Education information on CME and CPE credits.


  • 2019 ACCP Virtual Journal Club April | Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse - ON DEMAND

    Contains 5 Component(s), Includes Credits

    Presented by: Mohamad Shebley, PhD, Director & Volwiler Research Fellow, AbbVie Inc, Clinical Pharmacology & Pharmacometrics

    Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse - ON DEMAND

    ACCP Virtual Journal Club Webinars

    Live Session: Wednesday, April 24, 2019 from 2:00-3:00 PM EDT

    On Demand: April 24, 2019 to April 24, 2022

    See Handouts tab for Continuing Education information on CME and CPE credits.


  • 2017 ACCP Therapeutic Dilemmas May | At The Intersection of Environmental Air Pollutant Exposure, Genetic Variation and Asthma Control

    Contains 4 Component(s), Includes Credits

    ​Presented by Christopher Reilly, PhD, Associate Professor, Pharmacology and Toxicology, College of Pharmacy, University of Utah

    THERAPEUTIC DILEMMAS: At The Intersection of Environmental Air Pollutant Exposure, Genetic Variation and Asthma Control

    Wednesday, May 24, 2017; 2:00 - 3:00 PM ET

    Presented by Christopher Reilly, PhD, Associate Professor, Pharmacology and Toxicology, College of Pharmacy, University of Utah

    Why is this important to your practice?
    Air pollution is a global problem with serious health consequences. The effects of poor air quality on the efficacy of asthma control medications is of great concern for patients with respiratory disorders, their families, and healthcare providers. Exposures environmental or dietary xenobiotics are well recognized to impact drug disposition and response, such as through the induction or interactions with drug metabolizing enzymes or drug transporters. Additionally, drug responsiveness can also be modulated through receptor expression/activity within the cells lining airways. Genetic predisposition among some individuals may cause sensitization to air pollutants and interfere with the expected metabolic clearance of drugs, therefore requiring adaptation of asthma control regimens to treat more effectively an individual’s disease characteristics. This webinar will discuss new findings that connect pulmonary irritant sensing and xenobiotic clearance pathways with variations in asthma control as well as the resulting implications for treatment of asthma.

    Target Audience
    This webinar is intended for pharmacologists, pharmacists, clinicians or graduate/postgraduate trainees wishing to better understand the implications of environmental contaminants on the activity and efficacy of asthma control medication. This webinar is also suitable for pharmacology/biomedical graduate or medical students who are interested in respiratory disorders, clinical pharmacology, or integrative medicine. Additionally, individuals who are likely to be involved in facilitating patient care such as physician assistants, nursing, and pharmacy professionals may also benefit from this webinar.

    Goal and Objectives
    After completing this activity, the learner will be able to:

    1. Describe the mechanisms by which particulate matter, such as coal fly ash, can stimulate pro-inflammatory signaling cascades within the respiratory tract
    2. Discuss the potential consequences of exposure to particulate matter for those who suffer from asthma as it relates to respiratory tract physiology and medical interventions
    3. Among individuals with and without asthma, describe how genetic variation in TRP channels may predispose or influence susceptibility to inhaled particulate matter
    4. Discuss the ramifications of the findings for asthma control intervention for individuals living in different environments (i.e., different levels of exposure to particulate matter due to proximity to emissions)



    Christopher Reilly, PhD is an Associate Professor of Pharmacology and Toxicology and Associate Director of the Center for Human Toxicology at the University of Utah.  He received his PhD in Toxicology (1999) from Utah State University under Dr. Steven D. Aust. Dr. Reilly’s work focused on peroxidase- and oxygen radical-mediated toxicities and enzymatic mechanisms for iron loading and storage in ferritin. Dr. Reilly was a post-doctoral fellow from 1999-2001 at the University of Utah with Dr. Garold S. Yost and the Center for Human Toxicology where he studied mass spectrometry and catalytic mechanisms for the metabolism and bioactivation of xenobiotics by Cytochrome P450 enzymes, pulmonary-selective drug metabolism, and the pulmonary toxicity of pepper sprays. Through this work Dr. Reilly became interested in Transient Receptor Potential cation channels as mediators of xenobiotic toxicities in the lung. His work on the TRP ion channels has evolved and is now focused on interactions between TRP channels and airway inflammation and injury. His group’s work on CYP enzymes and TRP channels has fortuitously intersected leading to new insights on how genetic variations in CYPs and TRPs as well as exposure to environmental pollutants may affect asthma symptom control using traditional therapeutics.

    imageACPE Accreditation Statement

    The American College of Clinical Pharmacology is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. 

    • UAN Number:
      Live:  0238-0000-17-024-L01-P
      On Demand: 0238-0000-17-025-H01-P    Expires 5/26/2019
    • ACPE 1 Contact Hours
    • Knowledge Based Activity


    imageACCME Accreditation Statement

    The American College of Clinical Pharmacology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    Designation Statement
    The American College of Clinical Pharmacology designates this journal CE activity for 1 AMA PRA Category 1TM credit.  Physicians should only claim credit commensurate with the extent of the participation in the activity.

    Date of Issuance:  May 24, 2017
    Expiration Date:  May 24, 2020

    In order to receive CE credit, the learner must score 75% or better on the online post-test; complete an online evaluation and print a certificate.

    Moderators:
    Catherine Sherwin, PhD, MS, FCP and Jonathan Constance, PhD, are with the University of Utah School of Medicine.  As Moderators of the webinar. They developed the continuing education portion of this activity (target audience, goals and objectives and questions with solutions).  They have nothing to disclose.

    Presenter:
    Christopher Reilly, PhD is an Associate Professor of Pharmacology and Toxicology and Associate Director of the Center for Human Toxicology at the University of Utah and has nothing to disclose.

  • 2017 ACCP Webinars June | High Resolution Personalized Precision Therapeutics

    Contains 4 Component(s), Includes Credits

    Presented by Roland Valdes Jr.​, PhD, Univ of Louisville and Keri Donaldson​, MD, PhD, Penn State Coll of Medicine and Milton S. Hershey Medical Ctr

    High Resolution Personalized Precision Therapeutics

    Wednesday, June 14, 2017; 2:00 – 3:00 PM ET 

    Presented by Roland Valdes Jr., PhD, Univ of Louisville and Keri Donaldson, MD, PhD, Penn State Coll of Medicine and Milton S. Hershey Medical Ctr

    Why is this article important to your practice?
    A growing use of medications has led to both polypharmacy and addiction. Novel technologies and pharmacogenetic tools are available to increase the precision and personalization of drug selection. We will review and demonstrate the need for novel predictive algorithms to optimize therapeutic approaches based on pharmacogenetic and related molecular diagnostic testing.   

    Target Audience
    Clinical pharmacologist providing both research and clinical practice. Practitioners of pharmacology services.

    Goal and Objectives
    After completing this activity, the learner will be able to:

    1. Define the need and availability for personalizing drug therapy using pharmacogenetics and targeted informatics tools
    2. Apply novel algorithms based on PGx-testing to increase precision of drug selection and reduce polypharmacy 
    3. Demonstrate and compare options for providing targeted selection of drugs to reduce or avoid drug addiction

    Roland Valdes Jr., PhD is a Tenured Professor of Pathology and Laboratory Medicine and of Biochemistry and Molecular Biology at the University of Louisville’s School of Medicine. He has held the appointment as Distinguished University Scholar and as Senior Vice-Chairman for the Department of Pathology. He presently serves as Chief of Clinical Chemistry and Toxicology for the University Hospital and as Director of the Clinical Chemistry Postdoctoral Fellowship Program.  Dr. Valdes received his Ph.D. in Molecular Biophysics from the University of Virginia where he also completed postdoctoral training in Biochemistry and in Clinical Chemistry and Toxicology. Prior to his move to Louisville in 1989, Dr. Valdes was on the faculty at Washington University School of Medicine in St. Louis. He is a Diplomat of the American Board of Clinical Chemistry and a Fellow of the National Academy of Clinical Biochemistry.  Dr. Valdes is nationally and internationally recognized as a leader in advancing the profession of clinical chemistry and personalized medicine through his contributions in promoting clinical chemistry as a discipline via the scholarships of clinical service, research, and teaching.  Dr. Valdes has served on numerous federal/national committees such as CLIA and NIH Study Sections, and has served as President of several key professional organizations including the Clinical Ligand Assay Society (CLAS), the National Academy of Clinical Biochemistry (NACB), the Commission for Accreditation in Clinical Chemistry (ComACC), and, most recently, the Association of Clinical Scientists (ACS).  Dr. Valdes has also served on the Board of Directors of the American Association for Clinical Chemistry (AACC) and as a Director on the American Board of Clinical Chemistry (ABCC).  He has received several distinguished scientist and recognition awards from professional organizations such as the AACC, NACB, CLAS, and ACS and has authored more than 260 publications. Dr. Valdes holds several patents and is a pioneer in establishing the application of personalized and precision medicine via laboratory diagnostics by founding the first CLIA-accredited laboratory (PGXL Laboratories) focused on providing pharmacogenetic services. He continues working on developing novel laboratory services to enable the practice of precision/personalized medicine using advanced techniques in clinical chemistry.


    Keri Donaldson, MD, PhD is Medical Director and CEO of Prescient Medicine,  His work is fueled by an extensive background in the fields of pathology, genomics, and diagnostics. An active ad hoc reviewer and consultant, Dr. Donaldson has earned a reputation as an innovative member of the medical community and garnered key positions within respected institutions and national committees. Throughout his time with Penn State College of Medicine, he’s served as Assistant Professor of Pathology (also at Hershey Medical Center), Assistant Professor of Public Health Sciences (a joint appointment also at Hershey Medical Center), Assistant Professor of Medicine, and Assistant Professor of Biochemistry. He was certified as a diplomate of both the American Board of Pathology and the National Board of Medical Examiners, and is a frequent guest speaker at regional and national symposia. Dr. Donaldson holds a BS from Pennsylvania State University, an MD from Temple University School of Medicine, and a master of science in clinical epidemiology (MSCE) from the University of Pennsylvania School of Medicine.


    Knowledge Based Activity

    ACPE Accreditation Statement

    http://accp1.inreachce.com/content/owners/accp1/images/ACPE-black.pngThe American College of Clinical Pharmacology is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. 

    UAN Number:
    Live:  0238-0000-17-029-L01-P
    On Demand: 0238-0000-17-030-H01-P

    ACPE 1 Contact Hours


    ACCME Accreditation Statement

    The American College of Clinical Pharmacology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    Designation Statement

    The American College of Clinical Pharmacology designates this journal CE activity for 1 AMA PRA Category 1TM credit.  Physicians should only claim credit commensurate with the extent of the participation in the activity.

    In order to receive CE credit, the learner must score 75% or better on the online post-test and must complete an online evaluation.

    Date of Issuance:  6/14/17
    Expiration Date:  6/14/20

    In order to receive CE credit, the learner must score 75% or better on the online post-test; complete an online evaluation and print a certificate.

    Roland Valdes Jr., PhD, Professor, Univ of Louisville School of Medicine discloses that he receives consulting fees from PGXL Laboratories for being member of the Board of Directors and Univ of Louisville receives Grants from PGXL Laboratories.

  • 2017 ACCP Therapeutic Dilemmas July | How to Get Targeted Agents to the Patients Who Need Them

    Contains 4 Component(s), Includes Credits

    Presented by Joanna Yi, MD, Assistant Professor of Pediatric Hematology/Oncology, Baylor College of Medicine/ Texas Children’s Cancer and Hematology Centers

    THERAPEUTIC DILEMMAS: How to Get Targeted Agents to the Patients Who Need Them.  

    Tuesday, July 11th 2017; 2:00 – 3:00 pm ET

    Presented by Joanna Yi, MD, Assistant Professor of Pediatric Hematology/Oncology, Baylor College of Medicine/ Texas Children’s Cancer and Hematology Centers 

    Why is this topic important to your practice?
    Since the discovery of molecularly targeted agents such as Imatinib, there has been an ever-increasing drive to identify other targeted therapeutics to treat patients with more efficacy and less toxicity.  With the advent of genomic sequencing and more recently other "omics" technologies however, the information known about a patient's tumor has outstripped the physician's ability to prescribe medications precisely targeting all the known "drivers" of that disease. Precision medicine efforts to better match patients with targeted agents and innovative trial designs are underway and will be reviewed. Additionally, other methods to expedite and maximize the translation of targeted agents to patients will be addressed.  This will be illustrated with specific examples, including those from pediatric oncology.

    Target Audience
    This webinar is intended for pharmacologists, pharmacists, clinicians or graduate/postgraduate trainees wishing to better understand current developments in oncology to match patients with the appropriate molecularly targeted therapeutic agents and innovative trial designs with an emphasis on pediatric malignancies. This webinar is also suitable for pharmacology/biomedical graduate or medical students who are interested in oncology, clinical pharmacology or integrative medicine. Additionally, individuals who are likely to be involved in the facilitating patient care such as physician assistants, nursing and pharmacy professionals may also benefit from this webinar.

    Goal and Objectives After completing this activity, the learner will be able to:

    1. Identify obstacles blocking the translation of therapeutics in the lab to clinical trials
    2. List several strategies to accelerate the translation of therapeutics to clinical trials
    3. List reasons why pediatric drug discovery uniquely slower than desired
    4. Identify strategies which may aid in mitigating the development of resistance to targeted therapy

    Joanna Yi, MD, is an assistant professor of Pediatric Hematology/Oncology at Baylor College of Medicine/ Texas Children’s Cancer and Hematology Centers.  She completed her pediatric hematology/oncology fellowship at Dana-Farber/Boston Children’s Cancer and Hematology Centers, where she trained in the laboratory of James Bradner in epigenetics and chemical biology, focusing on the development of DOT1L inhibitors and BET bromodomain inhibitors.  She is a member of the Center for Drug Discovery at BCM, where she seeks to develop and translate targeted small molecules for challenging pediatric cancers. She serves as an intermediary between Texas Children’s Cancer Center labs to champion targets of interest through the drug screening platforms available at the Center for Drug Discovery, including the DNA-Encoded Technology platform.  Her lab has a specific interest chromatin-modifying small molecules, identifying and assessing top synergistic combinations for development pre-clinically and eventually clinically, and concurrently developing the necessary pharmacodynamics biomarkers for translation of these agents.   She is a member of the Developmental Therapeutics, Leukemia, and Neuroblastoma teams at Texas Children’s, and she will be chairing a first-in-children trial of a BET bromodomain inhibitor through the Children’s Oncology Group.

    image

    ACPE Accreditation Statement

    The American College of Clinical Pharmacology is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. 

    ACPE 1 Contact Hours 

    UAN Number: Live:  0238-0000-17-035-L05-P 

    UAN Number: On-demand: 0238-0000-17-036-H05-P 

    Knowledge Based Activity


    image

    ACCME Accreditation Statement

    The American College of Clinical Pharmacology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    Designation Statement

    The American College of Clinical Pharmacology designates this journal CE activity for 1 AMA PRA Category 1TM credit.  Physicians should only claim credit commensurate with the extent of the participation in the activity.

    In order to receive CE credit, the learner must score 75% or better on the online post-test and must complete an online evaluation.


     

    Date of Issuance:  July 11, 2017
    Expiration Date:  July 11, 2020

  • 2018 ACCP Virtual Journal Club February | Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration

    Contains 5 Component(s), Includes Credits

    Presented by: Manuel Gerónimo-Pardo, MD, PhD, Department of Anesthesiology, Complejo Hospitalario Universitario of Albacete, Spain. This article addresses a new dose form and therapeutic application of acetaminophen in multi-trauma patients.

    ACCP Virtual Journal Club - 2018 Feb - Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration

    Live webinar with the author: February 21, 2018   2:00 – 3:00 PM EST  

    On-demand webinar recording:  February 28, 2018 to February 28, 2021

    Why is this article important to your practice? 

    This article addresses a new dose form and therapeutic application of acetaminophen in multi-trauma patients. 

    Target Audience: Physicians, Pharmacists, and other clinicians involved in treating multi-trauma patients. 

    Goal and Objectives - After completing this activity, the learner will be able to:

    • Describe three potential clinical benefits of acetaminophen in the critically ill patient.
    • List the primary hepatic metabolic routes and the reported renal clearance of acetaminophen.
    • Describe the serum concentrations of acetaminophen needed to provide an antipyretic effect and analgesia.
    • Compare the total daily dose of acetaminophen needed to maintain a serum concentration of 10 ug/ml using multiple dosing and a continuous infusion.  

    To receive full credit, learners must pre-read the article located in the "handouts" tab.

    See Continuing Education Information in the "handouts" tab for more details.


  • 2018 ACCP Webinar June | How to be a Great Journal Peer Reviewer

    Contains 4 Component(s), Includes Credits

    Presented by: Joseph S. Bertino Jr., PharmD, FCP, FCCP, Editor-in-Chief, The Journal of Clinical Pharmacology and David J. Greenblatt MD, FCP, Editor-in-Chief Clinical Pharmacology in Drug Development. This webinar provides professional training on performing scientific journal manuscript peer reviews.

    ACCP 2018 Webinar - How to be a GREAT Journal Peer Reviewer

    Live webinar with the Editor-in-Chiefs: June 13, 2018   2:00 – 3:00 PM ET  

    On-demand webinar recording:  June 13, 2018 to June 13, 2021

    Why is this article important to your practice? 

    At the completion of this webinar participants will have a strong understanding and the skills to properly review a scientific manuscript, a professional competency applicable to journal peer reviewing across professions. Topics to be covered include: why one should serve as peer reviewer; the purpose of manuscript reviews; aspects of a great review; when to decline a review; confidentiality; a technical guide for reviews for each section of the manuscript; and writing the review.  

    Target Audience: 

    Researchers, Physicians, Pharmacists, and other professionals requiring training in the professional competencies of peer reviewing. 

    Learning Objectives: 

    After completing this activity, the learner will be able to:

    1. Describe why the peer review process is important;
    2. Explain how to review various sections of a scientific manuscript;
    3. Identify elements of writing a review that will be of benefit to the authors and to the Editor of the Journal.

    To receive full credit, learners must attend the complete live webinar or view the complete on-demand webinar; pass a post-course assessment with 75% or greater and complete an evaluation.